Cited by 391Ovarian cancer diagnosis and treatmentEpigenetics and DNA MethylationMetal complexes synthesis and properties

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Epigenetic Resensitization to Platinum in Ovarian Cancer

Open access

Matei, Daniela, Fang, Fang, Shen, Changyu, Schilder, Jeanne, Arnold, Alesha, Zeng, Yan, Berry, William A., Huang, Tim, Nephew, Kenneth P.·2012·Cancer Research

DOI 10.1158/0008-5472.can-11-3909PMC PMC3700422

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Preclinical studies have shown that hypomethylating agents reverse platinum resistance in ovarian cancer. In this phase II clinical trial, based upon the results of our phase I dose defining study, we tested the clinical and biologic activity of low-dose decitabine administered before carboplatin in platinum-resistant ovarian cancer patients. Among 17 patients with heavily pretreated and platinum-resistant ovarian cancer, the regimen induced a 35% objective response rate (RR) and progression-free survival (PFS) of 10.2 months, with nine patients (53%) free of progression at 6 months. Global and gene-specific DNA demethylation was achieved in peripheral blood mononuclear cells and tumors. The number of demethylated genes was greater (P < 0.05) in tumor biopsies from patients with PFS more than 6 versus less than 6 months (311 vs. 244 genes). Pathways enriched at baseline in tumors from patients with PFS more than 6 months included cytokine–cytokine receptor interactions, drug transporters, and mitogen-activated protein kinase, toll-like receptor and Jak-STAT signaling pathways, whereas those enriched in demethylated genes after decitabine treatment included pathways involved in cancer, Wnt signaling, and apoptosis (P < 0.01). Demethylation of MLH1, RASSF1A, HOXA10, and HOXA11 in tumors positively correlated with PFS (P < 0.05). Together, the results of this study suggest that low-dose decitabine altered DNA methylation of genes and cancer pathways, restoring sensitivity to carboplatin in patients with heavily pretreated ovarian cancer and resulting in a high RR and prolonged PFS. Cancer Res; 72(9); 2197–205. ©2012 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-3909

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
The Epigenomics of Cancer
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
A systems biology approach for pathway level analysisPreprint
Drăghici, S., Khatri, P., Tarca, A. L., Amin, K., Done, A., Voichiţa, C., Georgescu, C., & Romero, R. J. (2007) · Genome Research · doi:10.1101/gr.6202607 · Cited by 1,263
Toll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Platinum Resistance: The Role of DNA Repair Pathways
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 754
A cell biological view of Toll-like receptor function: regulation through compartmentalization
Barton, G. M., & Kagan, J. C. (2009) · Nature reviews. Immunology · doi:10.1038/nri2587 · Cited by 746
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Kantarjian, H. M., Oki, Y., Garcia‐Manero, G., Huang, X., O'Brien, S. M., Cortes, J. E., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z. E., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 684
DNA methylation analysis by pyrosequencing
Tost, J., & Gut, I. G. (2007) · Nature Protocols · doi:10.1038/nprot.2007.314 · Cited by 681
DNA Methylation Analysis by Pyrosequencing
Busato, F., & Tost, J. (2014) · Springer eBooks · doi:10.1007/978-1-4614-6418-1_799-1 · Cited by 500
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486
An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer
Teschendorff, A. E., Menon, U., Gentry‐Maharaj, A., Ramus, S. J., Gayther, S. A., Apostolidou, S., Jones, A., Lechner, M., Beck, S., Jacobs, I. J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008274 · Cited by 364
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
Duffy, M. J., Bonfrer, J. M. G., Kulpa, J., Rustin, G. J. S., Sölétormos, G., Torre, G. C., Tuxen, M. K., & Zwirner, M. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00130.x · Cited by 313
Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients
de Cáceres, I. I., Battagli, C., Esteller, M., Herman, J. G., Dulaimi, E., Edelson, M. I., Bergman, C. A., Ehya, H., Eisenberg, B. L., & Cairns, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1529 · Cited by 280
Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Shukla, S., Ohnuma, S., & Ambudkar, S. V. (2011) · Current Drug Targets · doi:10.2174/138945011795378540 · Cited by 233
Evolution of decitabine development
Jabbour, E. J., Issa, J. J., Garcia‐Manero, G., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23463 · Cited by 231
Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors
Appleton, K., MacKay, H. J., Judson, I. R., Plumb, J. A., McCormick, C., Strathdee, G. R., Lee, C., Barrett, S., Reade, S., Jadayel, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8688 · Cited by 228
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer
Li, M., Balch, C., Montgomery, J. S., Jeong, M., Chung, J. H., Yan, P. S., Huang, T. H. ‐., Kim, S., & Nephew, K. P. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-34 · Cited by 225
Self-citation
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients
Anzalone, A. A., Lettini, L., Fonsatti, E., & Maio, M. (2005) · The Women s Oncology Review · doi:10.1080/14733400500093346 · Cited by 221
DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment
Barton, C. A., Hacker, N. F., Clark, S. J., & O’Brien, P. M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.12.017 · Cited by 199
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers
Wei, S. H., Chen, C., Strathdee, G. R., Harnsomburana, J., Shyu, C., Rahmatpanah, F. B., Shi, H., Ng, S. W., Yan, P. S., Nephew, K. P., et al. (2011) · PubMed · doi:10.25405/ncl.34289580 · Cited by 198
Self-citation
Hypermethylation of Homeobox A10 by in Utero Diethylstilbestrol Exposure: An Epigenetic Mechanism for Altered Developmental Programming
Bromer, J. G., Wu, J., Zhou, Y., & Taylor, H. S. (2009) · Endocrinology · doi:10.1210/en.2009-0071 · Cited by 189
Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer
Fu, S., Hu, W., Iyer, R. B., Kavanagh, J. J., Coleman, R. L., Levenback, C. F., Sood, A. K., Wolf, J. K., Gershenson, D. M., Markman, M. M., et al. (2010) · Cancer · doi:10.1002/cncr.25701 · Cited by 183
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer
Fang, F., Balch, C., Schilder, J. M., Breen, T., Zhang, S., Shen, C., Li, L., Kulesavage, C., Snyder, A. J., Nephew, K. P., et al. (2010) · Cancer · doi:10.1002/cncr.25204 · Cited by 176
Self-citation
Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions
Lee, C.-W., Matulonis, U. A., & Castells, M. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.08.002 · Cited by 162
Minireview: Epigenetic Changes in Ovarian Cancer
Balch, C., Fang, F., Matei, D. E., Huang, T. H. ‐., & Nephew, K. P. (2009) · Endocrinology · doi:10.1210/en.2009-0404 · Cited by 146
Self-citation
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
Balch, C., Yan, P. S., Craft, T. R., Young, S. R. L., Skalnik, D. G., Huang, T. H. ‐., & Nephew, K. P. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0216 · Cited by 141
Self-citation
Evaluation of a 7-Day Continuous Intravenous Infusion of Decitabine: Inhibition of Promoter-Specific and Global Genomic DNA Methylation
Samlowski, W. E., Leachman, S. A., Wade, M. L., Cassidy, P. B., Porter-Gill, P. A., Busby, L. T., Wheeler, R. H., Boucher, K. M., Fitzpatrick, F. A., Jones, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.118 · Cited by 139
Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas
Stewart, D. J., Issa, J. J., Kurzrock, R., Nunez, M. I., Jelı́nek, J., Hong, D. S., Oki, Y., Guo, Z., Gupta, S. K., & Wistuba, I. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2196 · Cited by 139
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes
Calcagno, A. M., Fostel, J. M., To, K. K. W., Salcido, C. D., Martin, S. E., Chewning, K. J., Wu, C.-P., Varticovski, L., Bates, S. E., Caplen, N. J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604334 · Cited by 128
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
Sandercock, J., Parmar, M., Torri, V., & Qian, W. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600567 · Cited by 128
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
Glasspool, R. M., Brown, R. E., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R. H., Pledge, S., Paul, J., Mackean, M., Hall, G. D., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.116 · Cited by 125
Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance
Bram, E. E., Stark, M., Raz, S., & Assaraf, Y. G. (2009) · Neoplasia · doi:10.1593/neo.91314 · Cited by 119
ATM Regulates a RASSF1A-Dependent DNA Damage Response
Hamilton, G., Yee, K. S. Y., Scrace, S., & O’Neill, E. E. (2009) · Current Biology · doi:10.1016/j.cub.2009.10.040 · Cited by 116
A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer
Schwartsmann, G., Schünemann, H. J., Gorini, C., Filho, A. F. F., Garbino, C., Sabini, G., Musé, I., Leone, L. P. D., & Mans, D. R. A. (2000) · Investigational New Drugs · doi:10.1023/a:1006388031954 · Cited by 111
Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer
Woloszynska‐Read, A., Mhawech-Fauceglia, P. Y., Yu, J., Odunsi, K. O., & Karpf, A. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5279 · Cited by 110
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer
Matei, D. E., & Nephew, K. P. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.043 · Cited by 105
Self-citation
HOXA11 DNA methylation—A novel prognostic biomarker in ovarian cancer
Fiegl, H., Windbichler, G. H., Mueller‐Holzner, E., Goebel, G., Lechner, M., Jacobs, I. J., & Widschwendter, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23563 · Cited by 104
The Management of Recurrent Ovarian Cancer
Bukowski, R. M., Ozols, R. F., & Markman, M. M. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.03.012 · Cited by 87
Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix
Pohlmann, P. R., Leone, L. P. D., Cancella, A., Caldas, A. P. F., Lago, L. D., Campos, O., Monego, E., Rivoire, W. A., & Schwartsmann, G. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200210000-00015 · Cited by 86
Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell
Yu, W., Jin, C., Lou, X., Han, X., Li, L., He, Y., Zhang, H., Ma, K., Zhu, J., Cheng, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029450 · Cited by 74
Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer
Gadducci, A., Tana, R., TETI, G., Zanca, G., FANUCCHI, A., & Genazzani, A. R. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01063.x · Cited by 63
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis
Li, Y., Hu, W., Shen, D., Kavanagh, J. J., & Fu, S. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.08.030 · Cited by 61
Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers
Chan, K. C. A., & Lo, Y. M. D. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603625 · Cited by 60
Dna methylation in the immune system
Teitell, M. A., & Richardson, B. (2003) · Clinical Immunology · doi:10.1016/s1521-6616(03)00224-9 · Cited by 55
The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer
Duiker, E. W., van der Zee, A. G. J., de Graeff, P., Ek, W. B., Hollema, H., de Bock, G. H., de Jong, S., & de Vries, E. G. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.014 · Cited by 54
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance
See, H. T., Freedman, R. S., Kudelka, A. P., Burke, T. W., Gershenson, D. M., Tangjitgamol, S., & Kavanagh, J. J. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.15205.x · Cited by 54
A Novel Requirement for Janus Kinases as Mediators of Drug Resistance Induced by Fibroblast Growth Factor-2 in Human Cancer Cells
do Carmo, C. R., lyons-Lewis, J., Seckl, M. J., & Costa‐Pereira, A. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019861 · Cited by 41
Suppression of Ovarian Cancer Cell Tumorigenicity and Evasion of Cisplatin Resistance Using a Truncated Epidermal Growth Factor Receptor in a Rat Model
Chan, J. K., Pham, H. Q., You, X. J., Cloven, N. G., Burger, R. A., Rose, G. S., van Nostrand, K. M., Korc, M., DiSaia, P. J., & Fan, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-3013 · Cited by 31
Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Mahadevan, D., & Shirahatti, N. V. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009054863609 · Cited by 24
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
Glaysher, S., Gabriel, F. G., Johnson, P., Polak, M. E., Knight, L. A., Parker, K., Poole, M., Narayanan, A., & Cree, I. A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605817 · Cited by 24
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance
See, H. T., Freedman, R. S., Kudelka, A. P., et al. (2005) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-00009577-200503000-00004 · Cited by 19
Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer
Glasspool, R. M., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R., Pledge, S., Paul, J., Mackean, M., Halford, S. E. R., Kaye, S. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.5562 · Cited by 17
Introduction
Coleman, R. E. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.10.004 · Cited by 8

Sorted by citations

Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D. L., Böhm, S., Ahmed, A. A., Aspuria, P.-J. P., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S. P., Bookman, M. A., et al. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4019 · Cited by 1,395
Self-citation
Epigenetic Determinants of CancerPreprint
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,414
Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199

See all 391

Authors: Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P.
Affiliations: Indiana University Health (US)
Corresponding author: Matei, Daniela
Nephew, Kenneth P.
ORCID: Matei, Daniela
Fang, Fang
Shen, Changyu
Schilder, Jeanne
Zeng, Yan
Berry, William A.
Huang, Tim
Nephew, Kenneth P.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2012-04-30
Volume: 72
Issue: 9
Pages: 2197-2205
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-11-3909
PMC: PMC3700422
OpenAlex: W2151783390
Cited by: 390
References: 56
Citations by year: 2026: 20 · 2025: 11 · 2024: 27 · 2023: 23 · 2022: 21 · 2021: 33 · 2020: 21 · 2019: 38 · 2018: 36 · 2017: 33 · 2016: 35 · 2015: 39 · 2014: 32 · 2013: 18 · 2012: 3
FWCI: 34.25
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
IUScholarWorks (Indiana University) (submittedVersion)
Funders: U.S. Food and Drug Administration
National Cancer Institute (CA113001, R21CA133877, R01CA085289, U54CA113001, CA133877)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords: ovarian cancer, platinum resistance, decitabine, DNA demethylation, hypomethylating agents, carboplatin, progression-free survival, MLH1, RASSF1A, HOXA10, HOXA11, drug transporters, Wnt signaling, apoptosis, cytokine signaling pathways
MeSH terms: Decitabine, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Peritoneal Neoplasms, Carboplatin, Disease-Free Survival, DNA Methylation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epigenetic Resensitization to Platinum in Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks